BCIQ Profiles

Company Profile Report

CMS, BIO spin Part B data in opposite directions

CMS and the biopharma industry are presenting conflicting explanations for a spike in Medicare Part B premiums and deductibles.

CMS says the increases are “largely due to rising spending on physician-administered drugs” (see “Medicare Part B Premium Spike Could Create Pressure for International Reference Pricing.”).

BIO is

Read the full 474 word article

How to gain access

Continue reading with a
two-week free trial.